BioMarin Recruits Amgen R&D’s Friberg, Roche Dealmaker Sabry To Leadership Team

Third And Fourth C-Suite Changes Since November

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.

Paper plane leadership concept. Business teamwork, following leader, success, leadership illustration.
BioMarin has recruited new leadership during a period of change • Source: Shutterstock

BioMarin Pharmaceutical Inc. announced last November that longtime CEO Jean-Jacques Bienaimé would retire, with Genentech, Inc. CEO Alexander Hardy replacing him, and changes to its C-suite have continued since then. The company said on 21 August that Amgen, Inc. vice president of medical affairs, rare diseases Greg Friberg will become EVP and chief research and development officer, effective 30 September, and Hardy’s former colleague, retired Roche Pharma Partnering head James Sabry, has been named EVP and chief business officer, effective 7 October.

Key Takeaways

  • BioMarin recruited Amgen veteran Greg Friberg as its chief R&D officer and former Roche Partnering head James Sabry as its chief business officer.

The rare disease specialist said its current chief R&D officer, Hank Fuchs, will retire after 15 years with BioMarin, during...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Leadership

ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

 
• By Jung Won Shin

The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

Scrip-Leadership (Free-2): Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By Nabil

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 
• By Andrew McConaghie

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.